Rajesh Kumar advances antibody discovery and immunodiagnostics, with an issued HIV‑1 immunogen patent (2020/05470) and a provisional SARS‑CoV‑2 RBD mAb filing (202211005568). He leads funded programs building universal human antibody libraries and a 4–6 week mAb discovery pipeline, supporting vaccine potency/efficacy studies and work across assay development and non‑human primate models.